UTHR Q3 2017 Earnings — United Therapeutics Corporation Revenue & Financial Results | Market Cap Arena

UTHRUnited Therapeutics Corporation

$24B

Q3 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$446M+9.1% YoY

Gross Profit

$426M95.6% margin

Operating Income

$324M72.7% margin

Net Income

$276M62.0% margin

EPS (Diluted)

$6.27

QoQ Revenue Growth

+0.2%

Cash Flow

Operating Cash Flow

$259M

Free Cash Flow

$237M

Stock-Based Comp.

-$24M

Balance Sheet

Total Assets

$2.9B

Total Liabilities

$847M

Stockholders' Equity

$2.1B

Cash & Equivalents

$1.1B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$446M	$408M	+9.1%
Gross Profit	$426M	$385M	+10.8%
Operating Income	$324M	$239M	+35.7%
Net Income	$276M	$162M	+70.8%

Revenue Segments

Remodulin

$187M42%

Adcirca

$100M22%

Tyvaso

$89M20%

Orenitram

$53M12%

Unituxin

$17M4%